论文部分内容阅读
自从Perlman和作者进入抗生素研究以来,约在1953年抗生素的领域扩大到抗肿瘤抗生素,六十年代未扩大到酶抑制剂。低分子量酶抑制剂没有显著的抗菌活性,这些化合物和抗生素均称为微生物的次级代谢产物。它们的分离、结构测定和遗传研究表明,微生物是具有不同生物和药理作用的不同结构的有机化合物的宝库。据此原理,如果能建立正确的筛选方法,在微生物的培养滤液中寻找低分子量免疫调节剂是合理的。本文评述了筛选免疫调节剂和bestatin临床研究的最新结果。筛选免疫调节剂的新方法以很小剂量的革盖菌素类(Coriolingroup)抗生素及其活性衍生物(图1)给药,可增加小鼠脾内的抗体形成细胞数。在体外也观察到此作用;在1.5×10~7鼠脾中添加0.1ng二
Since Perlman and the author entered the study of antibiotics, the area of antibiotics expanded to anti-tumor antibiotics in about 1953 and not extended to enzyme inhibitors in the 1960s. Low molecular weight enzyme inhibitors have no significant antibacterial activity, and both these compounds and antibiotics are referred to as secondary metabolites of microorganisms. Their separation, structure determination and genetic studies have shown that microorganisms are a treasure trove of different structures of organic compounds with different biological and pharmacological effects. Based on this principle, it is reasonable to look for low molecular weight immunomodulators in the culture filtrate of microorganisms if the correct screening method can be established. This article reviews the latest results of a screening of immunomodulators and bestatin clinical studies. New Methods for Screening Immunomodulators The administration of very low doses of Coriolingroup antibiotics and their active derivatives (Figure 1) increases the number of antibody-forming cells in the spleen of mice. This effect was also observed in vitro; 0.1 ng was added to 1.5 × 10 -7 mouse spleen